Key Developments: Danaher Corp (DHR)

DHR on New York Consolidated

87.06USD
22 Dec 2014
Price Change (% chg)

$0.79 (+0.92%)
Prev Close
$86.27
Open
$86.74
Day's High
$87.21
Day's Low
$86.42
Volume
2,376,505
Avg. Vol
3,102,070
52-wk High
$87.21
52-wk Low
$70.12

Search Stocks

Latest Key Developments (Source: Significant Developments)

Danaher Corp appoints Thomas P. Joyce, Jr. as President And CEO
Tuesday, 2 Sep 2014 04:10pm EDT 

Danaher Corp:Announces that the company's Board of Directors has implemented its previously disclosed succession plan and will appoint Thomas P. Joyce, Jr. as President and Chief Executive Officer and a member of the Board of Directors, effective Sept. 9.  Full Article

Danaher Corp gives Q3 2014 earnings outlook; narrows FY 2014 earnings outlook
Thursday, 17 Jul 2014 06:06am EDT 

Danaher Corp:Expects Q3 2014 GAAP diluted net earnings per share will be in the range of $0.86 to $0.89.Narrowed diluted net earnings per share guidance for FY 2014 to $3.67 to $3.72 on a GAAP basis.Q3 2014 EPS of $0.96 - Thomson Reuters I/B/E/S.FY 2014 EPS of $3.75 - Thomson Reuters I/B/E/S.  Full Article

Danaher Corp subsidiary to acquire Siemens Healthcare Diagnostics' clinical microbiology business
Wednesday, 16 Jul 2014 04:00pm EDT 

Danaher Corp:Says Beckman Coulter, an indirect wholly-owned subsidiary, enters into a definitive agreement to purchase the clinical microbiology business of Siemens Healthcare Diagnostics.Transaction is expected to close in Q1 2015.Agreement is subject to applicable regulatory approvals and other customary closing conditions.  Full Article

Arseus closes Medical Universal divestment to Danaher Corp's Soredex
Wednesday, 30 Apr 2014 11:58am EDT 

Arseus NV:Closes divestments of Medical Universal and Eurotec.Medical Universal, located in Lyon and specialized in imports and distribution of imaging solutions in French market, sold to Soredex, part of PaloDEx Group Oy and Danaher Corp.  Full Article

Danaher Corporation announces CEO and President transition
Wednesday, 16 Apr 2014 04:01pm EDT 

Danaher Corporation:Executive Vice President Thomas P. Joyce, Jr. will succeed H. Lawrence Culp, Jr. as President and Chief Executive Officer upon Culp's retirement on March 1, 2015.Culp will continue at Danaher in advisory role into the first quarter of 2016.  Full Article

Danaher Corp gives Q2 2014 EPS guidance below analysts' estimates; reaffirms FY 2014 EPS guidance
Wednesday, 16 Apr 2014 04:01pm EDT 

Danaher Corp:Expects Q2 2014 GAAP diluted net earnings per share to be in the range of $0.90 to $0.94.Reaffirms FY 2014 GAAP diluted net earnings per share guidance of $3.60 to $3.75.Q2 2014 EPS of $0.96 - Thomson Reuters I/B/E/S.  Full Article

Danaher Corp declares dividend
Tuesday, 18 Feb 2014 06:00am EST 

Danaher Corp:Declares quarterly dividend of $0.10 per share payable on Apr. 25 to holders of record on Mar. 28.  Full Article

Danaher Corp gives Q1 2014 EPS outlook below analysts' estimates; reaffirms FY 2014 EPS outlook
Tuesday, 28 Jan 2014 06:00am EST 

Danaher Corp:Sees Q1 2014 GAAP diluted net earnings per share to be in the range of $0.76 to $0.80.Says it reaffirms FY 2014 diluted net earnings per share guidance of $3.60 to $3.75 with core revenue expected to grow between 2 pct and 4 pct.Q1 2014 EPS of $0.82 - Thomson Reuters I/B/E/S.  Full Article

Danaher Corp gives FY 2014 revenue guidance - Conference Call
Wednesday, 15 Jan 2014 04:30pm EST 

Danaher Corp:Expects $20 bln in terms of revenue for FY 2014.FY 2014 revenue of $20.1 bln - Thomson Reuters I/B/E/S.  Full Article

Danaher Corp reaffirms FY, Q4 2013 EPS guidance; gives FY 2014 guidance; EPS guidance below analysts' estimates
Thursday, 12 Dec 2013 06:00am EST 

Danaher Corp:Reaffirms FY 2013 adjusted diluted net earnings per share (EPS) guidance of $3.37 to $3.42.Reaffirms Q4 2013 adjusted diluted net EPS guidance of $0.91 to $0.96.Sees FY 2014 GAAP diluted net EPS to be in the range of $3.60 to $3.75.Says FY 2014 EPS guidance assumes FY 2014 core revenue growth of between 2 pct and 4 pct.FY 2013 EPS $3.41 - Thomson Reuters I/B/E/S Estimates.Q4 2013 EPS $0.95 - Thomson Reuters I/B/E/S Estimates.FY 2014 EPS $3.81, revenue $20.08 bln - Thomson Reuters I/B/E/S Estimates.  Full Article

Nobel Biocare confirms guidance, profit beats estimates

ZURICH, Nov 6 - Swiss dental implant maker Nobel Biocare, which has agreed to be bought by U.S. healthcare company Danaher, confirmed its full-year sales and profitability targets on Thursday as it posted quarterly profit that beat expectations.

Search Stocks